Hillsdale Investment Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-4,220
Closed -$542K 592
2021
Q1
$542K Buy
4,220
+50
+1% +$6.16K 0.05% 341
2020
Q4
$496K Buy
4,170
+4,100
+5,857% +$500K 0.05% 353
2020
Q3
$8K Buy
+70
New +$8.27K ﹤0.01% 508
2018
Q4
Sell
-520
Closed -$56K 595
2018
Q3
$56K Buy
520
+460
+767% +$50.5K 0.01% 294
2018
Q2
$7K Sell
60
-10
-14% -$1.04K ﹤0.01% 385
2018
Q1
$7K Hold
70
﹤0.01% 367
2017
Q4
$7K Sell
70
-530
-88% -$50.2K ﹤0.01% 378
2017
Q3
$57K Sell
600
-3,400
-85% -$361K 0.01% 312
2017
Q2
$445K Sell
4,000
-530
-12% -$56K 0.09% 188
2017
Q1
$445K Buy
4,530
+630
+16% +$60.1K 0.09% 177
2016
Q4
$358K Hold
3,900
0.07% 195
2016
Q3
$330K Buy
+3,900
New +$328K 0.09% 240
2016
Q2
Sell
-3,600
Closed -$257K 521
2016
Q1
$257K Hold
3,600
0.09% 282
2015
Q4
$256K Hold
3,600
0.1% 282
2015
Q3
$221K Sell
3,600
-1,000
-22% -$69.9K 0.07% 281
2015
Q2
$334K Hold
4,600
0.1% 201
2015
Q1
$354K Buy
+4,600
New +$329K 0.09% 218

Other funds holding DGX

Hillsdale Investment Management's DGX Position: Q2 2021 in Review

Hillsdale Investment Management sold out of Quest Diagnostics (DGX) in Q2 2021, closing a stake of 4,220 shares — an estimated $542K sold.

Hillsdale Investment Management first reported a position in DGX in Q1 2015 and held it in 17 quarters. The position peaked at $542K in Q1 2021. 815 funds tracked by Wall St. Rank hold DGX as of Q2 2021.

  • Hillsdale Investment Management reported no remaining Quest Diagnostics position as of Q2 2021 after selling out during the quarter.
  • Hillsdale Investment Management sold 4,220 Quest Diagnostics shares in Q2 2021, an estimated $542K.
  • Hillsdale Investment Management first reported a position in Quest Diagnostics in Q1 2015 and held it in 17 quarters.
  • Hillsdale Investment Management's Quest Diagnostics position peaked at $542K in Q1 2021.
  • 815 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2021.

Based on Hillsdale Investment Management's 13F filing for Q2 2021, filed 29 Jul 2021.